Aberrant Expression of A Disintegrin and Metalloproteinase With Thrombospondin Motifs 13 (ADAMTS13) in Pancreatic Cancer Leads to Dichotomic Functions

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers characterized by highly invasive growth into the surrounding peripancreatic fat tissue, where tumor cells can directly interact with adipocytes. Due to poor response to the currently available (radio)chemotherapies, there is an urgent need for advanced therapy concepts. The present study shows that ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin motifs 13), a key factor in blood coagulation, is significantly overexpressed in human PDAC. Immunohistochemical analysis revealed that ADAMTS13 expression is associated with prolonged survival and negatively correlated with vascular density. In vitro and in vivo experiments demonstrate its partial induction by leptin. Mechanistically, CRISPR/Cas-mediated ADAMTS13 knockout in PDAC cells resulted in reduced migration and invasion. In an avian xenograft tumor model, ADAMTS13 loss led to increased vascularization, decreased vascular length, and diminished tumor growth, accompanied by reduced expression of multiple key angiogenic and angioplastic factors. Furthermore, loss of ADAMTS13 was associated with decreased expression of mesenchymal markers. In conclusion, we identified an aberrant expression and alternative function of ADAMTS13 in PDAC linked to tumor progression, plasticity, and angiogenesis, partly induced by the peripancreatic fat tissue, making this metalloproteinase an interesting target for personalized therapies.

Keywords

ADAMTS13 / adipokines / pancreas / PDAC / peripancreatic adipose tissue / vascularization

References

[1] R. L. Siegel, A. N. Giaquinto, and A. Jemal, “Cancer Statistics, 2024,” CA: A Cancer Journal for Clinicians 74, no. 1 (2024): 12-49.

[2] L. Rahib, B. D. Smith, R. Aizenberg, A. B. Rosenzweig, J. M. Fleshman, and L. M. Matrisian, “Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States,” Cancer Research 74, no. 11 (2014): 2913-2921.

[3] T. Hackert and M. W. Buchler, “Pancreatic Cancer: Advances in Treatment, Results and Limitations,” Digestive Diseases 31, no. 1 (2013): 51-56.

[4] M. Slodkowski, M. Wronski, D. Karkocha, L. Kraj, K. Smigielska, and A. Jachnis, “Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma,” Cancers (Basel) 15, no. 9 (2023): 2584.

[5] A. Lugli, I. Zlobec, M. D. Berger, R. Kirsch, and I. D. Nagtegaal, “Tumour Budding in Solid Cancers,” Nature Reviews Clinical Oncology 18, no. 2 (2021): 101-115.

[6] H. Staiger and H. U. Haring, “Adipocytokines: Fat-Derived Humoral Mediators of Metabolic Homeostasis,” Experimental and Clinical Endocrinology & Diabetes 113, no. 2 (2005): 67-79.

[7] R. Z. Stolzenberg-Solomon, C. C. Newton, D. T. Silverman, et al., “Circulating Leptin and Risk of Pancreatic Cancer: A Pooled Analysis From 3 Cohorts,” American Journal of Epidemiology 182, no. 3 (2015): 187-197.

[8] Y. Xu, M. Tan, X. Tian, et al., “Leptin Receptor Mediates the Proliferation and Glucose Metabolism of Pancreatic Cancer Cells via AKT Pathway Activation,” Molecular Medicine Reports 21, no. 2 (2020): 945-952.

[9] K. Felix and M. M. Gaida, “Neutrophil-Derived Proteases in the Microenvironment of Pancreatic Cancer -Active Players in Tumor Progression,” International Journal of Biological Sciences 12, no. 3 (2016): 302-313.

[10] M. M. Gaida, T. G. Steffen, F. Gunther, et al., “Polymorphonuclear Neutrophils Promote Dyshesion of Tumor Cells and Elastase-Mediated Degradation of E-Cadherin in Pancreatic Tumors,” European Journal of Immunology 42, no. 12 (2012): 3369-3380.

[11] S. S. Apte, “ADAMTS Proteins: Concepts, Challenges, and Prospects,” Methods in Molecular Biology 2043 (2020): 1-12.

[12] R. Kelwick, I. Desanlis, G. N. Wheeler, and D. R. Edwards, “The ADAMTS (A Disintegrin and Metalloproteinase With Thrombospondin Motifs) family,” Genome Biology 16, no. 1 (2015): 113.

[13] A. A. Khorana, N. Mackman, A. Falanga, et al., “Cancer-Associated Venous Thromboembolism,” Nature Reviews Disease Primers 8, no. 1 (2022): 11.

[14] H. L. Obermeier, J. Riedl, C. Ay, et al., “The Role of ADAMTS-13 and Von Willebrand Factor in Cancer Patients: Results From the Vienna Cancer and Thrombosis Study,” Research and Practice in Thrombosis and Haemostasis 3, no. 3 (2019): 503-514.

[15] R. Z. He, J. H. Zheng, H. F. Yao, et al., “ADAMTS12 Promotes Migration and Epithelial-Mesenchymal Transition and Predicts Poor Prognosis for Pancreatic Cancer,” Hepatobiliary & Pancreatic Diseases International 22, no. 2 (2022): 169-178.

[16] M. O. Kilic, B. Aynekin, M. Bozer, et al., “Differentially Regulated ADAMTS1, 8, 9, and 18 in Pancreas Adenocarcinoma,” Przegląd Gastroenterologiczny 12, no. 4 (2017): 262-270.

[17] J. Xie, X. Zhou, R. Wang, et al., “Identification of Potential Diagnostic Biomarkers in MMPs for Pancreatic Carcinoma,” Medicine 100, no. 23 (2021): e26135.

[18] D. Ribatti, T. Annese, and R. Tamma, “The Use of the Chick Embryo CAM Assay in the Study of Angiogenic Activiy of Biomaterials,” Microvascular Research 131 (2020): 104026.

[19] Y. Shao, J. Chen, W. Freeman, et al., “Canonical Wnt Signaling Promotes Neovascularization Through Determination of Endothelial Progenitor Cell Fate via Metabolic Profile Regulation,” Stem Cells 37, no. 10 (2019): 1331-1343.

[20] C. Frere, B. Bournet, S. Gourgou, et al., “Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated with Outcomes,” Gastroenterology 158, no. 5 (2020): 1346-1358.

[21] C. K. Colonne, E. J. Favaloro, and L. Pasalic, “The Intriguing Connections Between Von Willebrand Factor, ADAMTS13 and Cancer,” Healthcare (Basel) 10, no. 3 (2022): 557.

[22] L. Oleksowicz, N. Bhagwati, and M. DeLeon-Fernandez, “Deficient Activity of von Willebrand's Factor-cleaving Protease in Patients With Disseminated Malignancies,” Cancer Research 59, no. 9 (1999): 2244-2250.

[23] B. H. Koo, D. Oh, S. Y. Chung, et al., “Deficiency of Von Willebrand Factor-Cleaving Protease Activity in the Plasma of Malignant Patients,” Thrombosis Research 105, no. 6 (2002): 471-476.

[24] M. Bohm, R. Gerlach, W. D. Beecken, T. Scheuer, I. Stier-Bruck, and I. Scharrer, “ADAMTS-13 Activity in Patients With Brain and Prostate Tumors Is Mildly Reduced, But Not Correlated to Stage of Malignancy and Metastasis,” Thrombosis Research 111, no. 1-2 (2003): 33-37.

[25] X. Hu, C. Jiang, N. Hu, and S. Hong, “ADAMTS1 induces Epithelial-Mesenchymal Transition Pathway in Non-Small Cell Lung Cancer by Regulating TGF-beta,” Aging (Albany NY) 15, no. 6 (2023): 2097-2114.

[26] R. Z. He, J. H. Zheng, H. F. Yao, et al., “ADAMTS12 Promotes Migration and Epithelial-Mesenchymal Transition and Predicts Poor Prognosis for Pancreatic Cancer,” Hepatobiliary & Pancreatic Diseases International 22, no. 2 (2023): 169-178.

[27] R. Kelwick, L. Wagstaff, J. Decock, et al., “Metalloproteinase-Dependent and -Independent Processes Contribute to Inhibition of Breast Cancer Cell Migration, Angiogenesis and Liver Metastasis by a Disintegrin and Metalloproteinase With Thrombospondin Motifs-15,” International Journal of Cancer 136, no. 4 (2015): E14-26.

[28] B. T. Emmer, D. Ginsburg, and K. C. Desch, “Von Willebrand Factor and ADAMTS13: Too Much or Too Little of a Good Thing?” Arteriosclerosis, Thrombosis, and Vascular Biology 36, no. 12 (2016): 2281-2282.

[29] I. Helfrich and D. Schadendorf, “Blood Vessel Maturation, Vascular Phenotype and Angiogenic Potential in Malignant Melanoma: One Step Forward for Overcoming Anti-Angiogenic Drug Resistance?,” Molecular Oncology 5, no. 2 (2011): 137-149.

[30] M. S. Alam, M. M. Gaida, F. Bergmann, et al., “Selective Inhibition of the p38 Alternative Activation Pathway in Infiltrating T Cells Inhibits Pancreatic Cancer Progression,” Nature Medicine 21, no. 11 (2015): 1337-1343.

[31] K. Takagi, T. Takada, and H. Amano, “A High Peripheral Microvessel Density Count Correlates With a Poor Prognosis in Pancreatic Cancer,” Journal of Gastroenterology 40, no. 4 (2005): 402-408.

[32] E. Katsuta, Q. Qi, X. Peng, S. N. Hochwald, L. Yan, and K. Takabe, “Pancreatic Adenocarcinomas With Mature Blood Vessels Have Better Overall Survival,” Scientific Reports 9, no. 1 (2019): 1310.

[33] P. Mayer, A. Kraft, H. R. Witzel, et al., “Restricted Water Diffusion in Diffusion-Weighted Magnetic Resonance Imaging in Pancreatic Cancer Is Associated With Tumor Hypoxia,” Cancers (Basel) 13, no. 1 (2020): 89.

[34] P. Mayer, C. Dinkic, R. Jesenofsky, et al., “Changes in the Microarchitecture of the Pancreatic Cancer Stroma Are Linked to Neutrophil-Dependent Reprogramming of Stellate Cells and Reflected by Diffusion-Weighted Magnetic Resonance Imaging,” Theranostics 8, no. 1 (2018): 13-30.

[35] T. Khoury and W. Sbeit, “Fatty Pancreas and Pancreatic Cancer: An Overlooked Association?” Journal of Clinical Medicine 11, no. 3 (2022): 763.

[36] P. Grochowski, B. Grosser, F. Sommer, et al., “The Concept of Stroma AReactive Invasion Front Areas (SARIFA) as a New Prognostic Biomarker for Lipid-Driven Cancers Holds True in Pancreatic Ductal Adenocarcinoma,” BMC cancer 24, no. 1 (2024): 768.

[37] K. S. Leifler, S. Svensson, A. Abrahamsson, et al., “Inflammation Induced by MMP-9 Enhances Tumor Regression of Experimental Breast Cancer,” Journal of Immunology 190, no. 8 (2013): 4420-4430.

[38] J. Lambert, K. Makin, S. Akbareian, et al., “ADAMTS-1 and Syndecan-4 Intersect in the Regulation of Cell Migration and Angiogenesis,” Journal of Cell Science 133, no. 7 (2020): jcs235762.

[39] H. Tang, M. Lee, E. H. Kim, D. Bishop, and G. M. Rodgers, “siRNA-Knockdown of ADAMTS-13 Modulates Endothelial Cell Angiogenesis,” Microvascular Research 113 (2017): 65-70.

[40] Y. Sun, J. Huang, and Z. Yang, “The Roles of ADAMTS in Angiogenesis and Cancer,” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 36, no. 6 (2015): 4039-4051.

[41] L. Wagstaff, R. Kelwick, J. Decock, and D. R. Edwards, “The Roles of ADAMTS Metalloproteinases in Tumorigenesis and Metastasis,” Frontiers in Bioscience (Landmark Edition) 16, no. 5 (2011): 1861-1872.

[42] R. Bacchetti, S. Yuan, and E. Rainero, “ADAMTS Proteases: Their Multifaceted Role in the Regulation of Cancer Metastasis,” Dis Res 4, no. 1 (2024): 40-52.

[43] G. C. Jones and G. P. Riley, “ADAMTS Proteinases: A Multi-Domain, Multi-Functional family With Roles in Extracellular Matrix Turnover and Arthritis,” Arthritis Research & Therapy 7, no. 4 (2005): 160-169.

[44] X. Zhang, K. Halvorsen, C. Z. Zhang, W. P. Wong, and T. A. Springer, “Mechanoenzymatic Cleavage of the Ultralarge Vascular Protein von Willebrand Factor,” Science 324, no. 5932 (2009): 1330-1334.

[45] S. D. Scilabra, L. Troeberg, K. Yamamoto, et al., “Differential Regulation of Extracellular Tissue Inhibitor of Metalloproteinases-3 Levels by Cell Membrane-Bound and Shed Low Density Lipoprotein Receptor-Related Protein 1,” Journal of Biological Chemistry 288, no. 1 (2013): 332-342.

[46] K. Yamamoto, K. Owen, A. E. Parker, et al., “Low Density Lipoprotein Receptor-Related Protein 1 (LRP1)-Mediated Endocytic Clearance of a Disintegrin and Metalloproteinase With Thrombospondin Motifs-4 (ADAMTS-4): Functional Differences of Non-Catalytic Domains of ADAMTS-4 and ADAMTS-5 in LRP1 Binding,” Journal of Biological Chemistry 289, no. 10 (2014): 6462-6474.

[47] K. Yamamoto, L. Troeberg, S. D. Scilabra, et al., “LRP-1-Mediated Endocytosis Regulates Extracellular Activity of ADAMTS-5 in Articular Cartilage,” Faseb Journal 27, no. 2 (2013): 511-521.

[48] S. Nandadasa, C. M. Kraft, L. W. Wang, et al., “Secreted Metalloproteases ADAMTS9 and ADAMTS20 Have a Non-Canonical Role in Ciliary Vesicle Growth During Ciliogenesis,” Nature Communications 10, no. 1 (2019): 953.

[49] J. D. Brierley, M. K. Gospodarowicz, and C. Wittekind, TNM Classification of Malignant Tumours (John Wiley & Sons, 2017).

[50] L. Stern, L. F. Boehme, M. R. Goetz, et al., “Potential Role of the Bitter Taste Receptor T2R14 in the Prolonged Survival and Enhanced Chemoresponsiveness Induced by apigenin,” International Journal of Oncology 62, no. 1 (2023): 6.

[51] P. Bankhead, M. B. Loughrey, J. A. Fernandez, et al., “QuPath: Open Source Software for Digital Pathology Image Analysis,” Scientific Reports 7, no. 1 (2017): 16878.

[52] D. C. Allred, J. M. Harvey, M. Berardo, and G. M. Clark, “Prognostic and Predictive Factors in Breast Cancer by Immunohistochemical Analysis,” Modern Pathology 11, no. 2 (1998): 155-168.

[53] U. Schmidt, M. Weigert, C. Broaddus, and G. Myers, Cell Detection With Star-Convex Polygons (Springer International Publishing, 2018).

[54] P. Mayer, A. Hausen, V. Steinle, et al., “The Radiomorphological Appearance of the Invasive Margin in Pancreatic Cancer Is Associated With Tumor Budding,” Langenbecks Archives of Surgery 409, no. 1 (2024): 167.

[55] F. Heigwer and G. Kerr, “Boutros M. E-CRISP: Fast CRISPR Target Site Identification,” Nature Methods 11, no. 2 (2014): 122-123.

[56] C. A. Schneider, W. S. Rasband, and K. W. Eliceiri, “NIH Image to ImageJ: 25 Years of Image Analysis,” Nature Methods 9, no. 7 (2012): 671-675.

[57] A. Suarez-Arnedo, F. Torres Figueroa, C. Clavijo, P. Arbelaez, J. C. Cruz, and C. Munoz-Camargo, “An Image J Plugin for the High Throughput Image Analysis of in Vitro Scratch Wound Healing Assays,” PLoS ONE 15, no. 7 (2020): e0232565.

[58] K. Frei, S. Schecher, T. Daher, et al., “Inhibition of the Cyclin K-CDK12 Complex Induces DNA Damage and Increases the Effect of Androgen Deprivation Therapy in Prostate Cancer,” International Journal of Cancer 154, no. 6 (2024): 1082-1096.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.